Jazz Pharmaceuticals' IPO: Taking Stock of VC Dilution
This article was originally published in Start Up
Executive Summary
The stockholder breakdown in Jazz Pharmaceuticals demonstrates how the company's founding VCs were significantly diluted by that company's massive Series B in 2004. As the company prepares for IPO it's worth considering how Ikaria Holdings' backers last month pulled in private equity support and managed to maintain their stakes in the company.
You may also be interested in...
Jazz Pharmaceuticals Improvises Its Way To A Turnaround
A day after specialty drug developer Jazz Pharmaceuticals Inc. announced plans to merge with Irish drugmaker Azur Pharma Ltd. in mid-September, the company had something new to celebrate. Jazz’s stock price reached an all-time high of $47.88 per share, giving the company a market valuation of almost exactly $2 billion.
Jazz Pharmaceuticals Improvises Its Way To A Turnaround
A day after specialty drug developer Jazz Pharmaceuticals Inc. announced plans to merge with Irish drugmaker Azur Pharma Ltd. in mid-September, the company had something new to celebrate. Jazz’s stock price reached an all-time high of $47.88 per share, giving the company a market valuation of almost exactly $2 billion.
Cash-Strapped Jazz Gets Stock Bump From Data On Fibromyalgia Candidate
Jazz Pharmaceuticals' stock price increased 39 percent on June 25, following the second announcement in a week of a successful Phase III trial for its fibromyalgia candidate, JZP-6 (sodium oxybate). The company's share price quickly retreated, dropping 56 cents on June 26 after analysts at Barclay's Capital downgraded the company because of concerns related to its financial health. Still the 21 percent increase in share value could position the specialty pharma to raise badly needed funds, given it has dwindling cash and defaulted on two recent quarterly interest payments on outstanding debt